Finally, development of companion diagnostic technologies to identify IPF patients most likely to benefit from AS-IV treatment through detection of PIK3CA expression levels or PI3K pathway activation status will enable truly personalized precision therapy. Here, PIK3CA is linked to idiopathic pulmonary fibrosis.